These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 32930105)

  • 1. Intramatricial low-dose secukinumab injection for nail psoriasis.
    He F; Long F; Tu J; Yin Z
    Indian J Dermatol Venereol Leprol; 2021; 87(1):116-119. PubMed ID: 32930105
    [No Abstract]   [Full Text] [Related]  

  • 2. Biologics in nail psoriasis.
    de Berker D
    Br J Dermatol; 2014 Feb; 170(2):236-7. PubMed ID: 24547718
    [No Abstract]   [Full Text] [Related]  

  • 3. Intramatricial injections for nail psoriasis: An open-label comparative study of triamcinolone, methotrexate, and cyclosporine.
    Mittal J; Mahajan BB
    Indian J Dermatol Venereol Leprol; 2018; 84(4):419-423. PubMed ID: 29536977
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nail Psoriasis: An Updated Review and Expert Opinion on Available Treatments, Including Biologics.
    Bardazzi F; Starace M; Bruni F; Magnano M; Piraccini BM; Alessandrini A
    Acta Derm Venereol; 2019 May; 99(6):516-523. PubMed ID: 30521057
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intramatricial injections for nail psoriasis: An open-label comparative study of triamcinolone, methotrexate, and cyclosporine.
    Ravindran S; Criton S
    Indian J Dermatol Venereol Leprol; 2019; 85(1):81-82. PubMed ID: 30457124
    [No Abstract]   [Full Text] [Related]  

  • 6. Intramatricial injection of anti-interleukin-17A antibody for six patients with nail psoriasis.
    He F; Long FY; Zhang ZQ; Xia RY; Lu Y; Yin ZQ
    Clin Exp Dermatol; 2022 Feb; 47(2):432-433. PubMed ID: 34510518
    [No Abstract]   [Full Text] [Related]  

  • 7. Nail Psoriasis Does Not Affect Skin Response to Ixekizumab in Patients With Moderate-To-Severe Psoriasis.
    Rich P; Goldblum O; Disch D; Lin CY; Merola JF; Elewski B
    J Drugs Dermatol; 2020 Aug; 19(8):741-746. PubMed ID: 32845588
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of secukinumab on the clinical activity and disease burden of nail psoriasis: 32-week results from the randomized placebo-controlled TRANSFIGURE trial.
    Reich K; Sullivan J; Arenberger P; Mrowietz U; Jazayeri S; Augustin M; Parneix A; Regnault P; You R; Milutinovic M
    Br J Dermatol; 2019 Nov; 181(5):954-966. PubMed ID: 30367462
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ixekizumab Is Effective in Subjects With Moderate to Severe Plaque Psoriasis With Significant Nail Involvement: Results From UNCOVER 3.
    Dennehy EB; Zhang L; Amato D; Goldblum O; Rich P
    J Drugs Dermatol; 2016 Aug; 15(8):958-61. PubMed ID: 27537996
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ustekinumab improves nail disease in patients with moderate-to-severe psoriasis: results from PHOENIX 1.
    Rich P; Bourcier M; Sofen H; Fakharzadeh S; Wasfi Y; Wang Y; Kerkmann U; Ghislain PD; Poulin Y;
    Br J Dermatol; 2014 Feb; 170(2):398-407. PubMed ID: 24117389
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Severe recalcitrant nail psoriasis responding dramatically to infliximab: report of two patients.
    Hussain W; Coulson I; Owen C
    Clin Exp Dermatol; 2008 Jul; 33(4):520-2. PubMed ID: 18462438
    [No Abstract]   [Full Text] [Related]  

  • 12. Efficacy and safety of switching to ixekizumab in secukinumab nonresponder patients with psoriasis: results from a multicentre experience.
    Conti A; Peccerillo F; Amerio P; Balato A; Bardazzi F; Bianchi L; Burlando M; Cannavò SP; Chiricozzi A; Dapavo P; De Simone C; Fargnoli MC; Gambardella A; Gisondi P; Malagoli P; Malara G; Mugheddu C; Offidani AM; Piaserico S; Prignano F; Stingeni L; Pellacani G
    Br J Dermatol; 2019 Jun; 180(6):1547-1548. PubMed ID: 30578668
    [No Abstract]   [Full Text] [Related]  

  • 13. Scalp and nail psoriasis.
    Lane-Brown MM
    Med J Aust; 1980 Jan; 1(2):82. PubMed ID: 7360098
    [No Abstract]   [Full Text] [Related]  

  • 14. Ixekizumab in nail psoriasis.
    Dattola A; Manfreda V; Mazzilli S; Bianchi L; Giunta A
    Dermatol Ther; 2020 May; 33(3):e13352. PubMed ID: 32232895
    [No Abstract]   [Full Text] [Related]  

  • 15. Marked improvement in nail psoriasis during treatment with adalimumab.
    Irla N; Yawalkar N
    Dermatology; 2009; 219(4):353-6. PubMed ID: 19851059
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of secukinumab in a pediatric patient leads to significant improvement in nail psoriasis and psoriatic arthritis.
    Wells LE; Evans T; Hilton R; Wine Lee L; Ruth N
    Pediatr Dermatol; 2019 May; 36(3):384-385. PubMed ID: 30811618
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of ixekizumab on nail psoriasis in paediatric patients with moderate-to-severe psoriasis: a post hoc analysis from IXORA-PEDS.
    Seyger MMB; Reich A; El Baou C; Schuster C; Riedl E; Paller AS
    J Eur Acad Dermatol Venereol; 2021 Dec; 35(12):e911-e913. PubMed ID: 34320259
    [No Abstract]   [Full Text] [Related]  

  • 18. Instability of topical ciclosporin emulsion for nail psoriasis.
    Prins AM; Vos K; Franssen EJ
    Dermatology; 2007; 215(4):362-3. PubMed ID: 17911999
    [No Abstract]   [Full Text] [Related]  

  • 19. Nail psoriasis improvement in a patient treated with fumaric acid esters.
    Vlachou C; Berth-Jones J
    J Dermatolog Treat; 2007; 18(3):175-7. PubMed ID: 17538807
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nail psoriasis: a combined treatment using calcipotriol cream and clobetasol propionate cream.
    Rigopoulos D; Ioannides D; Prastitis N; Katsambas A
    Acta Derm Venereol; 2002; 82(2):140. PubMed ID: 12125946
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.